

PATENT
674525-2001

equivalents. Any fee occasioned by this paper, including any additional claim fee, or any overpayment in such a fee, may be charged or credited to Deposit Account 50-0320.

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS:

1. (Amended Once) [Use of a *Notch*-ligand in the manufacture of a medicament for use in immunotherapy] A method of immunotherapy comprising administering a medicament comprised of a *Notch*-ligand to a patient in need thereof.

B 2. (Amended Once) [Use according to claim 1, wherein the immunotherapy involves the treatment of T-cell mediated disease or infection] The method of immunotherapy of claim 1, wherein the immunotherapy involves the treatment of a T-cell mediated disease or infection.

3. (Amended Once) [Use according to claim 2] The method of immunotherapy of claim 2, wherein the T-cell mediated disease or infection is due to any one or more of allergy, autoimmunity, graft rejection, [tumour] tumor induced aberrations to the T-cell system and infectious diseases such as those caused by Plasmodium species, Microfilariae, Helminths,

PATENT
674525-2001

Mycobacteria, HIV, Cytomegalovirus, Pseudomonas, Toxoplasma, Echinococcus, Haemophilus influenza type B, measles, Hepatitis C or Toxocara.

B¹
CMT
4. (Amended Once) [Use according to any of claims 1 or 3] The method of immunotherapy of any one of claims 1 or 3, wherein the Notch-ligand is selected from Serrate, Delta or fragments, derivatives or analogs thereof.

B²
23. (Amended Once) Compounds, Notch-ligands, derivatives, fragments or analogs thereof, detectable by [the assay of claim 22] an assay comprising contacting cells expressing Notch-protein or Notch ligand with a compound; and monitoring an increase or decrease in expression or processing of the protein or ligand.

Please add the following new claims:

sub
E1
27. (New) A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a Notch-ligand to a patient in need thereof.

B³
28. (New) The method of claim 27, wherein the T-cell mediated disease or infection is due to any one or more of allergy, autoimmunity, graft rejection, tumor induced aberrations to the T-cell system and infectious diseases such as those caused by Plasmodium species, Microfilariae, Helminths, Mycobacteria, HIV, Cytomegalovirus, Pseudomonas, Toxoplasma, Echinococcus, Haemophilus influenza type B, measles, Hepatitis C or Toxocara.